What is Alembic Pharmaceuticals' new FDA-approved eye drop for?

Alembic Pharmaceuticals' new FDA-approved eye drop, Travoprost Ophthalmic Solution, is for reducing elevated intraocular pressure in patients with glaucoma or ocular hypertension.

Is Alembic's Travoprost Ophthalmic Solution the same as Travatan Z?

Yes, Alembic's Travoprost Ophthalmic Solution USP, 0.004% is therapeutically equivalent to Sandoz's Travatan Z Ophthalmic Solution.

How many ANDA approvals does Alembic Pharmaceuticals have from USFDA?

Alembic Pharmaceuticals has a cumulative total of 232 ANDA approvals from the USFDA, including 212 final and 20 tentative approvals.

Home / Business and Economy / Alembic Pharma Gains USFDA Green Light for Glaucoma Treatment

Alembic Pharma Gains USFDA Green Light for Glaucoma Treatment

18 Dec, 2025

•

Summary

Alembic Pharmaceuticals received USFDA final approval for Travoprost Ophthalmic Solution.
This treatment is designed to reduce elevated intraocular pressure in glaucoma patients.
The approved drug is therapeutically equivalent to Sandoz's Travatan Z Ophthalmic Solution.

Alembic Pharma Gains USFDA Green Light for Glaucoma Treatment

Alembic Pharmaceuticals has announced a significant achievement with the US Food & Drug Administration granting final approval for its Travoprost Ophthalmic Solution USP, 0.004%. This newly approved generic medication is indicated for the crucial task of reducing elevated intraocular pressure in individuals diagnosed with open-angle glaucoma or ocular hypertension.